These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 16428490)

  • 1. Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patients.
    Dehqanzada ZA; Storrer CE; Hueman MT; Foley RJ; Harris KA; Jama YH; Kao TC; Shriver CD; Ponniah S; Peoples GE
    Clin Cancer Res; 2006 Jan; 12(2):478-86. PubMed ID: 16428490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.
    Peoples GE; Gurney JM; Hueman MT; Woll MM; Ryan GB; Storrer CE; Fisher C; Shriver CD; Ioannides CG; Ponniah S
    J Clin Oncol; 2005 Oct; 23(30):7536-45. PubMed ID: 16157940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine.
    Hueman MT; Stojadinovic A; Storrer CE; Foley RJ; Gurney JM; Shriver CD; Ponniah S; Peoples GE
    Breast Cancer Res Treat; 2006 Jul; 98(1):17-29. PubMed ID: 16758122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
    Holmes JP; Gates JD; Benavides LC; Hueman MT; Carmichael MG; Patil R; Craig D; Mittendorf EA; Stojadinovic A; Ponniah S; Peoples GE
    Cancer; 2008 Oct; 113(7):1666-75. PubMed ID: 18726994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
    Peoples GE; Holmes JP; Hueman MT; Mittendorf EA; Amin A; Khoo S; Dehqanzada ZA; Gurney JM; Woll MM; Ryan GB; Storrer CE; Craig D; Ioannides CG; Ponniah S
    Clin Cancer Res; 2008 Feb; 14(3):797-803. PubMed ID: 18245541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients.
    Hueman MT; Dehqanzada ZA; Novak TE; Gurney JM; Woll MM; Ryan GB; Storrer CE; Fisher C; McLeod DG; Ioannides CG; Ponniah S; Peoples GE
    Clin Cancer Res; 2005 Oct; 11(20):7470-9. PubMed ID: 16243821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial.
    Patil R; Clifton GT; Holmes JP; Amin A; Carmichael MG; Gates JD; Benavides LH; Hueman MT; Ponniah S; Peoples GE
    J Am Coll Surg; 2010 Feb; 210(2):140-7. PubMed ID: 20113933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex technology.
    Dehqanzada ZA; Storrer CE; Hueman MT; Foley RJ; Harris KA; Jama YH; Shriver CD; Ponniah S; Peoples GE
    Oncol Rep; 2007 Mar; 17(3):687-94. PubMed ID: 17273752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.
    Knutson KL; Schiffman K; Cheever MA; Disis ML
    Clin Cancer Res; 2002 May; 8(5):1014-8. PubMed ID: 12006513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.
    Holmes JP; Benavides LC; Gates JD; Carmichael MG; Hueman MT; Mittendorf EA; Murray JL; Amin A; Craig D; von Hofe E; Ponniah S; Peoples GE
    J Clin Oncol; 2008 Jul; 26(20):3426-33. PubMed ID: 18612158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.
    Disis ML; Grabstein KH; Sleath PR; Cheever MA
    Clin Cancer Res; 1999 Jun; 5(6):1289-97. PubMed ID: 10389911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer.
    Perez SA; Kallinteris NL; Bisias S; Tzonis PK; Georgakopoulou K; Varla-Leftherioti M; Papamichail M; Thanos A; von Hofe E; Baxevanis CN
    Clin Cancer Res; 2010 Jul; 16(13):3495-506. PubMed ID: 20466887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine.
    Disis ML; Schiffman K; Guthrie K; Salazar LG; Knutson KL; Goodell V; dela Rosa C; Cheever MA
    J Clin Oncol; 2004 May; 22(10):1916-25. PubMed ID: 15143085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial.
    Mittendorf EA; Storrer CE; Foley RJ; Harris K; Jama Y; Shriver CD; Ponniah S; Peoples GE
    Cancer; 2006 Jun; 106(11):2309-17. PubMed ID: 16596621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
    Sandri MT; Johansson HA; Zorzino L; Salvatici M; Passerini R; Maisonneuve P; Rocca A; Peruzzotti G; Colleoni M
    Cancer; 2007 Aug; 110(3):509-17. PubMed ID: 17559147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
    Müller V; Witzel I; Lück HJ; Köhler G; von Minckwitz G; Möbus V; Sattler D; Wilczak W; Löning T; Jänicke F; Pantel K; Thomssen C
    Breast Cancer Res Treat; 2004 Jul; 86(1):9-18. PubMed ID: 15218357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles.
    Salazar LG; Fikes J; Southwood S; Ishioka G; Knutson KL; Gooley TA; Schiffman K; Disis ML
    Clin Cancer Res; 2003 Nov; 9(15):5559-65. PubMed ID: 14654536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot study.
    Stojadinovic A; Mittendorf EA; Holmes JP; Amin A; Hueman MT; Ponniah S; Peoples GE
    Ann Surg Oncol; 2007 Dec; 14(12):3359-68. PubMed ID: 17906897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer.
    Murray JL; Gillogly ME; Przepiorka D; Brewer H; Ibrahim NK; Booser DJ; Hortobagyi GN; Kudelka AP; Grabstein KH; Cheever MA; Ioannides CG
    Clin Cancer Res; 2002 Nov; 8(11):3407-18. PubMed ID: 12429628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer.
    Schippinger W; Regitnig P; Bauernhofer T; Ploner F; Hofmann G; Krippl P; Wehrschütz M; Lax S; Carney W; Neumann R; Wernecke KD; Samonigg H
    Oncol Rep; 2004 Jun; 11(6):1331-6. PubMed ID: 15138574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.